Article
SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia
10 Apr 2021
Abstract excerpt
Abstract We discovered that the survival and growth of many primary acute myeloid leukemia (AML) samples and cell lines, but not normal CD34+ cells, are dependent on SIRT5, a lysine deacylase implicated in regulating multiple metabolic pathways. Dependence on SIRT5 is genotype agnostic and extends to RAS- and p53-mutated AML. Results were comparable between SIRT5 knockdown and SIRT5 inhibition using NRD167, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
